Glaxo holds its breath
A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
Sanofi and Glaxo scrape a Covid vaccine latecomer
After a long wait the groups’ jab delivers mediocre efficacy.
Pfizer waits for paediatric Comirnaty data to mature
A look at the past week’s Covid winners and losers finds Pfizer, unusually, among the latter.
Another step backwards for Valneva
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
